Piper Jaffray upgraded BioCryst Pharma (NASDAQ: BCRX) from Neutral to Overweight with a price target of $8.00 (from $5.00) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE